Orbsen Therapeutics is a regenerative medicine company based in Galway, Ireland.
Using proprietary technology, we are developing ground-breaking stromal cell treatments to address some of today’s most challenging diseases.
Stromal cells hold great promise as an alternative to drugs and surgical procedures for treating a wide range of medical conditions including heart disease, arterial disease of the limbs, diabetes complications, arthritis and other inflammatory conditions. The treatment potential is linked to the cells’ natural capacity to dampen inflammation and promote healing, repair and regeneration of damaged tissues.
Orbsen has discovered and patented a unique method for purifying these rare, therapeutic cells and developing them for clinical use. The cells can be selected from a single donor, expanded and frozen to generate many doses of a high-margin, “off-the-shelf” therapeutic product.
Between 2013 and 2015, Orbsen collaborated with some 30 independent research laboratories across the EU to secure more than €35 million in EU funding to accelerate the clinical development of our cell therapy. Orbsen’s proprietary cell therapy will soon begin testing for safety and efficacy in clinical trials in patients suffering from Diabetic Foot Ulcers, Autoimmune Liver Disease, Corneal Transplant Rejection, Diabetic Kidney Disease and Acute Respiratory Distress Syndrome.